Endocrine, Metabolic, and Immune Pathogenesis of Postmenopausal Osteoporosis. Is there a Therapeutic Role in Natural Products?


Journal

Endocrine, metabolic & immune disorders drug targets
ISSN: 2212-3873
Titre abrégé: Endocr Metab Immune Disord Drug Targets
Pays: United Arab Emirates
ID NLM: 101269157

Informations de publication

Date de publication:
2023
Historique:
received: 28 11 2022
revised: 01 03 2023
accepted: 20 03 2023
medline: 29 8 2023
pubmed: 4 4 2023
entrez: 3 4 2023
Statut: ppublish

Résumé

Bone health relies on the equilibrium between resorption and new bone generation. Postmenopausal osteoporosis depends on estrogen deficiency which favorite bone resorption and elevated risk of fractures. Moreover, osteoporosis is characterized by a high release of proinflammatory cytokines suggesting the role of the immune system in the pathogenesis of this complex disease (immunoporosis). To review the pathophysiology of osteoporosis from an endocrinological and immunological viewpoint and treatments with a specific focus on nutraceuticals. PubMed/MEDLINE, Scopus, Google Scholar, and institutional web site were searched. Original articles and reviews were screened and selected by September 2022. The activation of the Gut Microbiota-Bone Axis contributes to bone health by releasing several metabolites, including short-chain fatty acids (SCFAs), that facilitate bone mineralization directly and indirectly by the induction of T regulatory cells, triggering anti-inflammatory pathways. Treatments of postmenopausal osteoporosis are based on lifestyle changes, calcium and vitamin D supplementation, and anti-resorptive and anabolic agents, such as bisphosphonates, Denosumab, Teriparatide, Romosozumab. However, phytoestrogens, polyphenols, probiotics, and polyunsaturated fatty acids may improve bone health by several mechanisms, including anti-inflammatory properties. Specific clinical trials are needed to assess the efficacy/effectiveness of the possible anti-osteoporotic activity of natural products as add on to background treatment.

Sections du résumé

BACKGROUND BACKGROUND
Bone health relies on the equilibrium between resorption and new bone generation. Postmenopausal osteoporosis depends on estrogen deficiency which favorite bone resorption and elevated risk of fractures. Moreover, osteoporosis is characterized by a high release of proinflammatory cytokines suggesting the role of the immune system in the pathogenesis of this complex disease (immunoporosis).
AIMS OBJECTIVE
To review the pathophysiology of osteoporosis from an endocrinological and immunological viewpoint and treatments with a specific focus on nutraceuticals.
METHODS METHODS
PubMed/MEDLINE, Scopus, Google Scholar, and institutional web site were searched. Original articles and reviews were screened and selected by September 2022.
RESULTS RESULTS
The activation of the Gut Microbiota-Bone Axis contributes to bone health by releasing several metabolites, including short-chain fatty acids (SCFAs), that facilitate bone mineralization directly and indirectly by the induction of T regulatory cells, triggering anti-inflammatory pathways.
CONCLUSION CONCLUSIONS
Treatments of postmenopausal osteoporosis are based on lifestyle changes, calcium and vitamin D supplementation, and anti-resorptive and anabolic agents, such as bisphosphonates, Denosumab, Teriparatide, Romosozumab. However, phytoestrogens, polyphenols, probiotics, and polyunsaturated fatty acids may improve bone health by several mechanisms, including anti-inflammatory properties. Specific clinical trials are needed to assess the efficacy/effectiveness of the possible anti-osteoporotic activity of natural products as add on to background treatment.

Identifiants

pubmed: 37005529
pii: EMIDDT-EPUB-130541
doi: 10.2174/1871530323666230330121301
doi:

Substances chimiques

Biological Products 0
Bone Density Conservation Agents 0
Diphosphonates 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1278-1290

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Giuseppe Lisco (G)

Interdisciplinary Department of Medicine, School of Medicine, University of Bari Aldo Moro, Bari, Italy.

Domenico Triggiani (D)

Interdisciplinary Department of Medicine, School of Medicine, University of Bari Aldo Moro, Bari, Italy.

Vito Angelo Giagulli (VA)

Interdisciplinary Department of Medicine, School of Medicine, University of Bari Aldo Moro, Bari, Italy.

Giovanni De Pergola (G)

Interdisciplinary Department of Medicine, School of Medicine, University of Bari Aldo Moro, Bari, Italy.

Edoardo Guastamacchia (E)

Interdisciplinary Department of Medicine, School of Medicine, University of Bari Aldo Moro, Bari, Italy.

Giuseppina Piazzolla (G)

Interdisciplinary Department of Medicine, School of Medicine, University of Bari Aldo Moro, Bari, Italy.

Emilio Jirillo (E)

Interdisciplinary Department of Medicine, School of Medicine, University of Bari Aldo Moro, Bari, Italy.

Vincenzo Triggiani (V)

Interdisciplinary Department of Medicine, School of Medicine, University of Bari Aldo Moro, Bari, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH